MS
Insider
Maged Shenouda
Chief Financial OfficerMaged Shenouda (Chief Financial Officer) filed 2 Form 4 reports in the trailing twelve months (2 purchases, 0 sales), most often in Relmada Therapeutics, Inc. (RLMD). Across 1 priced purchase filing, the average 21-session return was +56.9% from execution and +48.8% from disclosure (delay-adjusted; derived). The largest single filing was $1.1M of RLMD (500,000 sh × $2.20, as filed), executed Nov 5 2025.
Add to watchlistReturn, ttmiAverage return per filing, trailing twelve months
+56.9%
avg across 1 priced filings
Delay-adjustediThe same average, entered at disclosure dates
+48.8%
same 1 filings, from disclosure
Filings, ttm
2
2 buys · 0 sells
Median delay
2d
execution → disclosure
Volume, ttmiDollar value disclosed in the trailing twelve months
$1.9M
shares × price, as filed
Last traded
Sep 10
Filed Sep 11
Median ADV $7.1M across their filed names
50% of their measured filings could not be priced (delisted or unquoted names). The returns above cover only what still trades.
Open performance→Volume by month
Buys $1.9M
Sells $0
Shares × price, as filed · by filing month · past 24 months
Sectors filed on
Healthcare
2 filings
Sector per market data · by filing · past 12 months
Most traded names
RLMDRecent filings
RLMDPURCHASE
Relmada Therapeutics, Inc.
View filing →
$844K200,000 sh across 2 lots
Exec Sep 9
Filed Sep 11 · 7:30 AM ET RLMDPURCHASE Relmada Therapeutics, Inc. View filing → $1.1M
500,000 sh × $2.20
Exec Nov 5 2025
Filed Nov 6 2025 · 7:30 AM ET